ClinicalTrials.gg
RecruitingNCT06944522exPDite-2Updated Nov 2, 2026

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

A Phase 3 interventional study of bemdaneprocel and Sham surgery in Parkinsons Disease (PD), sponsored by BlueRock Therapeutics. Recruiting at 43 sites in 3 countries. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by BlueRock Therapeutics (part of Bayer) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 2, 2026Eligibility revisedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Parkinson Disease by Bayer — 6 open to participants now, 8 under way, 1 of them phase 3. Parkinson Disease · Bayer.

Started
2025
with 1 other
Phase 3
Only one
of the 12
Registered
8th of 12
by date

Among the 12 studies in Parkinson Disease by Bayer, this one is one of 2 that started in 2025, is the only one in phase 3, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 12 studies in Parkinson Disease by Bayer are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Parkinson Disease by Bayer, or all of them as a file.
02

Study summary

Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

Read the detailed description

The BRT-DA01-301 study is a Phase 3, multicenter, randomized, sham surgery-controlled, double-blind study involving approximately 102 participants with Parkinson's Disease (PD). Participants will be randomized in a 2:1 ratio to either receive bemdaneprocel or undergo sham surgery. The study includes an immunosuppression regimen and placebo equivalents to maintain blinding. The primary objective is to evaluate the efficacy of bemdaneprocel on motor symptoms in participants with PD. The secondary objective is to evaluate the effects of bemdaneprocel on Motor function, Quality of life, Non-motor symptoms of PD, Disease severity, and Use of PD medications or therapies compared with participants who undergo sham surgery. Participants will be followed for at least 18 months in the double-blind period and up to five years if they receive bemdaneprocel.

03

Conditions studied

  • Parkinsons Disease (PD)

Browse trials for

Keywords

  • exPDite-2
  • Cell Therapy
  • Cellular Therapy
  • Dopaminergic Neuronal Cell Therapy
  • Parkinsons Disease
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of clinically established PD as defined by the International Parkinson and Movement Disorders Society
  • Individual of any sex ≥45 to ≤75 years of age at
  • Robust and clear response to DA therapy as defined by MDS-UPDRS Part III
  • ≥4 and \<12 years from time of PD diagnosis at informed consent
  • Must demonstrate responsiveness to levodopa therapy
  • Receiving medical therapy for the treatment of PD symptoms
  • ≥2.5 hours of daily OFF-time
  • Vaccinated per current national guidelines or local practice for patients with altered immunocompetence

Exclusion criteria

Exclusion Criteria:

  • PD presenting with recurrent falls
  • Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis, or clinical features suggestive of a neurodegenerative disease other than PD, including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia
  • Any current or relevant previous history of serious, severe, or unstable physical, neurological, or psychiatric illness that may interfere with study participation, participant's safety, or assessment of endpoints per investigator's judgment
  • History of gene therapy or cell therapy for a neurological or intercerebral condition
  • Prior treatment with intrajejunal or subcutaneous infusion therapies for PD
  • Prior surgical or radiation therapy to the brain, including deep brain stimulation (DBS) and lesion therapy, or prior history of intradural spinal cord surgery
  • to surgery, general anesthesia, cell therapy, , or other required drugs, or anything that prevents use of PET or MRI
  • Any history or evidence of infection with or ; any active infection with , CMV, syphilis, or latent tuberculosis; and any condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments. Exceptions: Treated and resolved TB, syphilis and/or HCV are not exclusionary
  • Current or previously active malignant disease within the past 5 years
  • Chronic immunosuppressive therapy
  • Receipt of another therapy within 5 half-lives of the active treatment
  • Pregnancy or breastfeeding
  • Unable to comply with study requirements for any reason
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    Group A

    Bemdaneprocel will be administered on Day 0

    Biological: bemdaneprocel

  • Sham comparator
    Group B

    Sham surgery will be performed on Day 0

    Procedure: Sham surgery

Interventions

  • Biologicalbemdaneprocel

    Investigational cell therapy comprising midbrain dopaminergic neuron progenitors derived from human embryonic stem cells

    Also known as: MSK-DA01, BRT-DA01

  • ProcedureSham surgery

    Sham surgery will be performed on Day 0

06

What researchers measure

Primary outcomes

  1. Change from baseline in PD diary measure of ON-time without troublesome dyskinesia, adjusted for a 16-hour waking day

    Time frame: From baseline to Week 78

Secondary outcomes

  1. Change from baseline in PD diary measure of OFF-time, adjusted for a 16-hour waking day

    Time frame: From baseline to Week 78

  2. Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in the off-medication state. Part III score can range from 0 to 132, with lower scores being better.

    Time frame: From baseline to Week 78

  3. Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score. Part II score can range from 0 to 52, with lower scores being better.

    Time frame: From baseline to Week 78

  4. Percentage change from baseline in 18F-DOPA uptake in the posterior putamen.

    Time frame: From baseline to Week 78

  5. Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index. Summary index score can range from 0 to 100, with lower scores being better.

    Time frame: From baseline to Week 78

  6. Incidence and severity of treatment-emergent adverse events

    Time frame: From baseline to month 60

07

Study locations

43 of 43 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2028, 40 months after the start.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's planned 40 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2027 → Oct 2028 and completion Mar 2032 → Aug 2034.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 25, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Oct 2028was Mar 2027
CompletionEst.
Aug 2034was Mar 2032
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Oct 2028
Oct 30, 2026
Study completion
Mar 2032→Aug 2034
Oct 30, 2026
Eligibility
Criteria revised in 2 updates
What changed on Oct 30, 2026
Exclusion criteria
  • EditedHistory of gene therapy or cell therapy for a neurological or intercerebral condition
  • EditedAny activehistory or evidence of infection (including but not limited to HIV, HCV,with HBV, CMV, syphilis, or tuberculosis) orHIV; and any condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments. Exceptions: Treated and resolved TB, syphilis and/or HCV are not exclusionary
  • AddedUnable to comply with study requirements for any reason
What changed on Nov 2, 2026
Exclusion criteria
  • EditedAny history or evidence of infection with HBV or HIV; any active infection with HCV, CMV, syphilis, or latent tuberculosis; and any condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments. Exceptions: Treated and resolved TB, syphilis and/or HCV are not exclusionary
across 2 updates, Oct 30, 2026 – Nov 2, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedPercentage change from baseline in 18F-DOPA uptake in the posterior putamen.Time frame: From baseline to Week 78
Oct 30, 2026
Show all 2 updates
  1. Nov 2, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedAny history or evidence of infection with HBV or HIV; any active infection with HCV, CMV, syphilis, or latent tuberculosis; and any condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments. Exceptions: Treated and resolved TB, syphilis and/or HCV are not exclusionary
  2. Oct 30, 2026
    Primary completion Mar 2027→Oct 2028
    Study completion Mar 2032→Aug 2034
    Eligibility 2 exclusion criteria edited, 1 added
    What changed in the criteria
    Exclusion criteria
    • EditedHistory of gene therapy or cell therapy for a neurological or intercerebral condition
    • EditedAny activehistory or evidence of infection (including but not limited to HIV, HCV,with HBV, CMV, syphilis, or tuberculosis) orHIV; and any condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments. Exceptions: Treated and resolved TB, syphilis and/or HCV are not exclusionary
    • AddedUnable to comply with study requirements for any reason
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedPercentage change from baseline in 18F-DOPA uptake in the posterior putamen.Time frame: From baseline to Week 78
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06944522
Collaborators
Bayer
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Jun 17, 2025
Primary completion
Oct 2028 (estimated)
Completion
Aug 2034 (estimated)
Last update
Nov 2, 2026

Study contacts

Patient Engagement
Contact
clinicaltrials@bluerocktx.com
1-877-380-3967

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion